Guidance on OBMEAs for rare diseases
This guidance explores how outcomes-based managed entry agreements (OBMEAs) can be used for rare disease treatments, using real-world examples like nusinersen and tisagenlecleucel. It highlights best practices for setting up these agreements, such as clear outcome measures, data collection systems, and stakeholder collaboration, while cautioning that OBMEAs are complex and should only be used when necessary.
At a glance
Use when
There is high unmet need and uncertainty in clinical or economic evidence for a rare disease treatment; when conditional reimbursement based on real-world outcomes is feasible; when robust data collection systems exist or can be established
Avoid when
Data collection infrastructure is weak or fragmented; when stakeholder alignment is lacking; for treatments with well-established efficacy and safety profiles; when simpler pricing or reimbursement mechanisms are sufficient
Inputs
Information on clinical and economic uncertainties, treatment outcomes, national regulatory and reimbursement frameworks, stakeholder roles (payer, manufacturer, clinician, patient), data collection infrastructure
Outputs
Recommendations for OBMEA design, implementation strategies, data monitoring protocols, stakeholder engagement practices, and proposals for international collaboration
How it works
The study reviews the implementation of OBMEAs for two rare disease treatments—nusinersen (for spinal muscular atrophy) and tisagenlecleucel (for certain cancers)—across EU countries, Australia, and Canada. It examines both individual- and population-based OBMEAs, focusing on design, data collection mechanisms (e.g., national registries, clinical databases), stakeholder involvement (including payers, manufacturers, clinicians, and in some cases patients), and processes for monitoring and re-evaluation. The analysis identifies variability in agreement duration, reporting practices, and data quality assurance, and recommends improved transparency, harmonized frameworks, and international collaboration through shared data platforms.
- Project
- IMPACT HTA
- Funding
- Horizon 2020
- Project status
- Completed 2021
- HTA domains
- Aspects Beyond HTA
- Categories
- Pricing/Payer
- Technology
- Non-specific
- Assumptions
- OBMEAs are appropriate when there is significant uncertainty in clinical or economic evidence at time of approval; data collection systems can support robust monitoring; stakeholders are willing to collaborate; outcomes measured reflect treatment value
- Strengths
- Draws on real-world case studies across multiple jurisdictions; identifies transferable best practices; emphasizes patient involvement and data quality; supports harmonization and knowledge sharing
- Limitations
- Findings are based on a limited number of treatments and countries; not all OBMEA details are publicly available; implementation challenges may vary by healthcare system; long-term outcomes and re-appraisal processes are not fully documented
- Also known as
- Outcomes-Based Managed Entry Agreements for Rare Diseases, OBMEA Implementation Guidance
Questions this answers
- › What are outcomes-based managed entry agreements (OBMEAs) and how are they used for rare disease treatments?
- › How do different countries implement OBMEAs for treatments like nusinersen and tisagenlecleucel?
- › What types of outcomes are used in OBMEAs and how is treatment continuation monitored?
- › How is data collected and verified in OBMEA schemes?
- › What role do patients and clinicians play in OBMEA implementation?
- › How can countries improve OBMEA design and evaluation for rare diseases?
Related methods
Similar by meaning
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.